Holen Sie sich die Stockscreener-App
1.015
3.33%
-0.035
Schlusskurs vom Vortag:
$1.05
Offen:
$1.05
24-Stunden-Volumen:
291.05K
Relative Volume:
0.37
Marktkapitalisierung:
$71.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.51M
KGV:
-0.50
EPS:
-2.03
Netto-Cashflow:
$-95.89M
1W Leistung:
-6.88%
1M Leistung:
+6.73%
6M Leistung:
-47.41%
1J Leistung:
-56.44%
1-Tages-Spanne:
$1.01
$1.06
1-Wochen-Bereich:
$0.92
$1.19
52-Wochen-Spanne:
$0.70
$3.1399
Vor Biopharma Inc Stock (VOR) Company Profile
Firmenname
Vor Biopharma Inc
Sektor
Branche
Telefon
617-655-6580
Adresse
100 CAMBRIDGEPARK DRIVE, CAMBRIDGE
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-26 | Eingeleitet | Wedbush | Outperform |
| 2022-04-27 | Eingeleitet | Goldman | Neutral |
| 2021-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-12-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-12-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-10-19 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-25 | Eingeleitet | B. Riley Securities | Buy |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-03-03 | Eingeleitet | Evercore ISI | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Sell |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vor Biopharma Inc Aktie (VOR) Neueste Nachrichten
California Biotech Reports Positive QOL Improvements in Program - Streetwise Reports
Biotech Co. Says New Data Show Success of Type 1 Diabetes Treatment - Streetwise Reports
Insider Selling: Attar Eyal C., Vor Biopharma Inc [VOR] CHIEF MEDICAL OFFICER divested 14,645 shares - Knox Daily
A better buy-in window may exist right now for Vor Biopharma Inc (VOR) - SETE News
Analytical Lens: Exploring Vor Biopharma Inc (VOR)’s Financial Story Through Ratios - The Dwinnex
VOR’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely - Simply Wall St
Biotech Working on 'Functional Cure' for Type 1 Diabetes - Streetwise Reports
MA Biotech Reports Positive Meeting with FDA - Streetwise Reports
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
How did Vor Biopharma Inc (VOR) fare last session? - US Post News
Brokerages Set Vor Biopharma Inc. (NYSE:VOR) PT at $10.92 - MarketBeat
JMP Securities Reiterates Market Outperform Rating for Vor Biopharma (NYSE:VOR) - Defense World
HC Wainwright Reiterates “Buy” Rating for Vor Biopharma (NYSE:VOR) - Defense World
Principal Financial Group Inc. Has $10.28 Million Position in Molson Coors Beverage (NYSE:TAP) - Defense World
Thesis Gold (CVE:TAU) PT Raised to C$3.00 - Defense World
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday? - MSN
Vor Biopharma (NYSE:VOR) Earns Market Outperform Rating from JMP Securities - MarketBeat
Vor’s stem cell transplant delays cancer relapse - BioWorld Online
Vor Biopharma Inc (VOR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Mass. Biopharma Reports Positive Data & Announces New Program - Streetwise Reports
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday? - Benzinga
Vor Biopharma stock holds price target, buy rating on positive study data - Investing.com
Ncino Inc. [NCNO] stock for 19,355 USD was sold by Orenstein Gregory - Knox Daily
A company insider recently sold 7,500 shares of Ardelyx Inc [ARDX]. Should You Sale? - Knox Daily
CHIEF MEDICAL OFFICER Attar Eyal C. sold 14,645 shares of Vor Biopharma Inc [VOR] - Knox Daily
Gaining Ground: Vor Biopharma Inc (VOR) Closes Lower at 0.82, Down -2.37 - The Dwinnex
Baird reiterates Outperform on Vor Biopharma as trem-cel data derisks safety profile - Investing.com
Vor Bio Announces New Clinical Data from Its Ongoing Phase 1/2 VBP101 Study of Patients with Relapsed/Refractory AML Receiving trem-cel Followed by Mylotarg? - Marketscreener.com
Vor Bio reports promising AML treatment data - Investing.com India
Aqua Metals Inc [AQMS] Shares Fall Approximately -81.89% Over the Year - Knox Daily
Vor Bio reports promising AML treatment data - Investing.com
Vor Bio stock rallies post-market on trem-cel study data (NASDAQ:VOR) - Seeking Alpha
Vor Biopharma Advances Innovative Blood Cancer Therapies - TipRanks
Vor Bio reports promising AML treatment data By Investing.com - Investing.com UK
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies - GlobeNewswire
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies - Yahoo Finance
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely - Yahoo Finance
Dundee (TSE:DC.A) Shares Cross Above 50 Day Moving Average of $1.34 - Defense World
Examining Vor Biopharma Inc (VOR) stock is warranted - US Post News
Vor Biopharma Inc (VOR) expanding its growth trajectory ahead - SETE News
Vor Biopharma faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Vor Bio to Participate in Upcoming Investor Conferences - GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences - Marketscreener.com
Vor Bio to Participate in Upcoming Investor Conferences - Yahoo Finance
PureTech Health plc – Half-Year Report - Business Wire
Investing in Vor Biopharma Inc (VOR) might be an excellent idea, but the stock is currently overvalued/undervalued - US Post News
Vor Biopharma Inc (VOR) stock: A year of ups and downs - US Post News
Vanguard Group Inc. Has $4.30 Million Holdings in Vor Biopharma Inc. (NYSE:VOR) - Defense World
Vor Biopharma Inc. (NYSE:VOR) Receives $10.92 Consensus PT from Brokerages - Defense World
Financial Survey: B.O.S. Better Online Solutions (NASDAQ:BOSC) versus Invent Ventures (OTCMKTS:IDEA) - Defense World
Finanzdaten der Vor Biopharma Inc-Aktie (VOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.25%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):